N-acetylcysteine (NAC)
Also called: NAC, N-acetyl-L-cysteine, acetylcysteine
N-acetylcysteine (NAC) is derived from the amino acid L-cysteine. It was approved as a drug in the United States in 1963 (inhaled acetylcysteine, Mucomyst) and is also used as an antidote for acetaminophen overdose.
- Category
- Amino acid and protein
- Forms
- N-acetyl-L-cysteine (synthetic), oral
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2023 meta-analysis (Therapeutic Advances in Respiratory Disease) included 9 RCTs of long-term oral NAC versus placebo in adults with COPD (1,061 NAC and 1,076 placebo patients). [4]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BImmune system and infection1 topic
CBrain, mood and sleep1 topic
XLungs and airways1 topic
XCancer1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Exacerbations and lung function in COPD | X | A 2023 meta-analysis of 9 placebo-controlled RCTs (1,061 NAC and 1,076 placebo patients) found long-term oral NAC did not reduce acute exacerbations or slow lung-volume decline. [4] |
| Inflammatory markers in adults | B | A 2020 meta-analysis of 24 RCTs (1,057 participants; 400–2000 mg/day for 1–80 weeks) found oral NAC lowered CRP (−0.61 mg/L) and IL-6, with high heterogeneity; other inflammatory markers did not change. [5] |
| Compulsive disorders and depression | C | MSK describes the studies as mixed on whether NAC can help compulsive disorders, and on depression. [1] |
| Second head and neck or lung tumors | X | MSK reports that a large trial found NAC did not inhibit formation of secondary head and neck or lung tumors. [1] |
Main constituents: N-acetylcysteine, derived from the amino acid L-cysteine [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Inflammatory-marker RCTs used 400 to 2000 mg/day for 1 to 80 weeks. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox (Acetylcysteine, last update November 7, 2016): likelihood score E, unlikely cause of clinically apparent liver injury …
Details and sources - Pregnancy and breastfeedingHealth Canada's N-acetyl-L-cysteine monograph requires the caution to ask a health care practitioner before use if pregnant or breastfeeding.
1 statement in the profile.
Details and sources - Interactions with medicines3 listed
Nitroglycerin; Antibiotics and nitroglycerin; Imipramine and escitalopram
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada NNHPD N-acetyl-L-cysteine monograph (December 19, 2025), adults 18 years and older: not to exceed 600 milligrams per day, taken with a …
Details and sources
- LiverTox: likelihood score E (unlikely cause of clinically apparent liver injury); side effects of the oral formulation can include disagreeable taste, diarrhea, nausea and vomiting. [2]
- MSK lists common oral adverse reactions as gastrointestinal disturbance, diarrhea, nausea, vomiting, fatigue, conjunctival irritation and skin rash; others include hypotension, anaphylaxis, asthma attacks and headache. [1]
- MSK states it is controversial whether antioxidants like NAC can lessen or negate cancer treatment effects, and cites an animal study in which NAC appeared to accelerate lung cancer growth; patients are advised to consult their oncologist. [1]
- In the COPD meta-analysis, adverse events did not differ significantly between NAC (832 patients) and placebo (846 patients). [4]
- Health Canada requires cautions to ask a health care practitioner before use if pregnant or breastfeeding, or if you have kidney stones. [3]
Interactions
| With | What happens |
|---|---|
| Nitroglycerin | MSK: adding NAC caused severe headaches due to an added vasodilation effect; MSK advises not taking NAC with nitroglycerin. [1] |
| Antibiotics and nitroglycerin | Health Canada's monograph contraindication: "Do not use if you are taking antibiotics or nitroglycerin." [3] |
| Imipramine and escitalopram | In animal models, NAC may increase the effects of these antidepressants; clinical relevance has yet to be determined. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- MSK notes an unpleasant product odor that required masking. [1]
Regulatory status
- US: FDA states that NAC is excluded from the dietary supplement definition under the FD&C Act because it was approved as a new drug before it was marketed as a dietary supplement or as a food. [6]
- US: FDA's final guidance (August 2022) states its intent to exercise enforcement discretion for certain NAC-containing products that would be lawfully marketed dietary supplements if NAC were not excluded, unless it identifies safety-related concerns during its ongoing review, until it completes notice-and-comment rulemaking or denies the citizen petition's request for rulemaking. On November 29, 2023, FDA stated it had completed its review of safety information related to NAC, which will go through peer review next. [6]
- Canada: Health Canada's N-acetyl-L-cysteine monograph (December 19, 2025) covers oral use as a source of antioxidant, not to exceed 600 mg per day. [3]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- N-acetyl-L-cysteine (proper name L-alpha-Acetamido-beta-mercaptopropionic acid); synthetic preparation Amino acid derivative (acetylated L-cysteine) [P8]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA states that NAC is excluded from the dietary supplement definition under the FD&C Act because it was approved as a new drug before it was marketed as a dietary supplement or as a food. Under its final guidance (August 2022), FDA intends to exercise enforcement discretion for certain NAC-containing products that would be lawfully marketed dietary supplements if NAC were not excluded, unless it identifies safety-related concerns. [P1]
- The guidance states FDA's "intent to exercise enforcement discretion with respect to the sale and distribution of certain products that contain N-acetyl-L-cysteine (NAC)" (content current as of 08/01/2022). [P2]
- FDA's published NDI notification list has 1 entry naming an NAC compound, N-Acetylcysteine (NAC) ethyl ester (NDI 669 submitted 2010-08-09); none names NAC itself. The list gives the date of FDA's response letter but not what it said. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- LiverTox (Acetylcysteine, last update November 7, 2016): likelihood score E, unlikely cause of clinically apparent liver injury; it has not been linked to significant serum enzyme elevations during therapy. [P6]
Interactions with medicines
- Nitroglycerin: MSK: adding NAC caused severe headaches due to an added vasodilation effect. [P7]
- Antibiotics and nitroglycerin: Health Canada's monograph contraindication: "Do not use if you are taking antibiotics or nitroglycerin." [P8]
- Imipramine and escitalopram: In animal models, NAC may increase the effects of these antidepressants; clinical relevance has yet to be determined. [P7]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; a firm may petition FDA for an exemption under 111.75(a)(1)(ii). [P9]
Supply and conservation
- Health Canada's monograph lists the preparation of N-acetyl-L-cysteine as synthetic. [P8]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada NNHPD N-acetyl-L-cysteine monograph (December 19, 2025), adults 18 years and older: not to exceed 600 milligrams per day, taken with a meal. [P8]
Pregnancy and breastfeeding
- Health Canada's N-acetyl-L-cysteine monograph requires the caution to ask a health care practitioner before use if pregnant or breastfeeding. [P8]
Sources for this profile
- U.S. Food and Drug Administration. FDA Releases Final Guidance on Enforcement Discretion for Certain NAC Products (content current as of 11/29/2023), 2023-11-29. fda.gov
- U.S. Food and Drug Administration. Guidance for Industry: Policy Regarding N-acetyl-L-cysteine (August 2022; content current as of 08/01/2022), 2022-08-01. fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports index (TR-000 to TR-606, checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Acetylcysteine (Last Update November 7, 2016), 2016-11-07. ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: N-Acetylcysteine (Last Updated October 21, 2022), 2022-10-21. mskcc.org
- Health Canada, NNHPD. Monograph: N-Acetyl-L-Cysteine (date 2025-12-19), 2025-12-19. webprod.hc-sc.gc.ca
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Memorial Sloan Kettering Cancer Center. About Herbs: N-Acetylcysteine (Last Updated October 21, 2022), 2022-10-21. mskcc.org
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Acetylcysteine (Last Update November 7, 2016), 2016-11-07. ncbi.nlm.nih.gov
- Health Canada, NNHPD. Monograph: N-Acetyl-L-Cysteine (date 2025-12-19), 2025-12-19. webprod.hc-sc.gc.ca
- Huang C, et al. The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. Ther Adv Respir Dis 2023;17:17534666231158563 (PMID 36927162), 2023. pubmed.ncbi.nlm.nih.gov
- Askari M, et al. The effects of N-acetylcysteine on serum level of inflammatory biomarkers in adults: findings from a systematic review and meta-analysis of randomized clinical trials. Cytokine 2020;135:155239 (PMID 32799012), 2020-11. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. FDA Releases Final Guidance on Enforcement Discretion for Certain NAC Products (content current as of 11/29/2023), 2023-11-29. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in amino acid and protein: 5-HTP (5-hydroxytryptophan) · Beta-alanine · BPC-157 · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · Glutathione · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.